Finance

Beta
Lists
SNN:NYSE
Smith & Nephew PLC
$30.61
-0.78%
(-0.24) 1D
$30.61
0.00% (0.00)
After hours
Closed: Jun 5, 4:00:05 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SNN...
Open
$30.96
High
$31.08
Low
$30.59
Mkt. cap
12.82B
Avg. vol.
1.33M
Volume
1.75M
Dividend
2.55%
Quarterly dividend
$0.20
Ex-dividend date
Mar 26, 2026
P/E ratio
21.38
52-wk high
$38.79
52-wk low
$28.40
EPS
$1.43
Beta
0.55
Shares outstanding
425.10M
No. of employees
17K
Open
$30.96
High
$31.08
Low
$30.59
Mkt. cap
12.82B
Avg. vol.
1.33M
Volume
1.75M
Dividend
2.55%
Quarterly dividend
$0.20
Ex-dividend date
Mar 26, 2026
P/E ratio
21.38
52-wk high
$38.79
52-wk low
$28.40
EPS
$1.43
Beta
0.55
Shares outstanding
425.10M
No. of employees
17K
Analyst outlook
Analyst Ratings
Based on 4 analysts giving stock ratings to SNN in the past 3 months
Hold
Buy
0
Hold
4
Sell
0
12 month forecast
Based on 4 Wall Street analysts offering 12 month price targets for SNN in the last 3 months.
Highest
Current $30.61
$35.11 (+14.70%)
Average
$32.32 (+5.59%)
Lowest
$30.00 (-1.99%)
News stories
From sources across the web
Profile
Smith & Nephew plc, also known as Smith+Nephew, is a British multinational medical equipment manufacturing company headquartered in Watford, England. It is an international producer of advanced wound management products, arthroscopy products, trauma and clinical therapy products, and orthopaedic reconstruction products. Its products are sold in over 100 countries. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index. Wikipedia
About Smith & Nephew PLC
CEODeepak Nath
Employees17K
Founded1856
Headquarters-
SectorMedical device
Last report
Mar 2, 2026
Fiscal period
Q4 2025
EPS / Est. (USD)
$29.55 / -
0.00%miss
Revenue / Est. (USD)
1.60B / 1.68B
-4.41%miss
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
1.48B
1.48B
1.60B
1.60B
Cost of goods sold
435.00M
435.00M
543.50M
543.50M
Cost of revenue
435.00M
435.00M
543.50M
543.50M
Research and development expenses
71.50M
71.50M
75.50M
75.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
759.50M
759.50M
758.50M
758.50M
Operating expense
831.00M
831.00M
834.00M
834.00M
Total operating expenses
1.27B
1.27B
1.38B
1.38B
Operating income
214.50M
214.50M
224.00M
224.00M
Other non operating income
-6.00M
-6.00M
1.00M
1.00M
EBT including unusual items
181.00M
181.00M
208.50M
208.50M
EBT excluding unusual items
181.00M
181.00M
253.00M
253.00M
Income tax expense
34.50M
34.50M
42.50M
42.50M
Effective tax rate
19.06%
19.06%
20.38%
20.38%
Other operating expenses
-
-
-
-
Net income
146.50M
146.50M
166.00M
166.00M
Net profit margin
9.90%
9.90%
10.37%
10.37%
Earnings per share
-
-
-
-
Interest and investment income
7.50M
7.50M
6.50M
6.50M
Interest expense
-34.50M
-34.50M
-35.50M
-35.50M
Net interest expenses
-27.00M
-27.00M
-29.00M
-29.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
351.00M
351.00M
317.00M
317.00M
Gain or loss from assets sale
5.50M
5.50M
6.00M
6.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more